InvaGen Pharmaceuticals Inc., a subsidiary of Cipla Ltd., is acquiring the Nasdaq-listed Avenue Therapeutics Inc., with an eye on its late-stage asset, intravenous (IV) tramadol, which could address a significant gap in the US post-operative pain management market against the backdrop of the opioid crisis there.
Cipla Acquires Avenue, Primes Play In Pain Amid US Opioid Crisis
Cipla has struck a 'de-risked' deal to acquire the specialty firm Avenue Therapeutics, Inc, for up to $215m as it readies a niche play in the US pain management segment amid the opioid crisis.
